CO6260065A2 - Uso de dronedarona o una sal aceptable farmaceuticamente de esta para la preparacion de un medicamento para regular el nivel de potasio en la sangre - Google Patents
Uso de dronedarona o una sal aceptable farmaceuticamente de esta para la preparacion de un medicamento para regular el nivel de potasio en la sangreInfo
- Publication number
- CO6260065A2 CO6260065A2 CO10128693A CO10128693A CO6260065A2 CO 6260065 A2 CO6260065 A2 CO 6260065A2 CO 10128693 A CO10128693 A CO 10128693A CO 10128693 A CO10128693 A CO 10128693A CO 6260065 A2 CO6260065 A2 CO 6260065A2
- Authority
- CO
- Colombia
- Prior art keywords
- preparation
- dronedarone
- potassium
- blood
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
Abstract
1.- Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para usarse en la regulación del nivel de potasio en la sangre. 2.- Uso según la Reivindicación 1, para la preparación de un medicamento para usarse en la prevención y/o tratamiento de la hipocalemia. 3.- Uso según cualquiera de las Reivindicaciones 1 y 2, caracterizado porque los pacientes tratados tienen historias de fibrilación atrial o aleteo atrial. 4.- Uso según una de las Reivindicaciones 1 a 3, caracterizado porque los pacientes reciben un tratamiento basado en diuréticos. 5.- Uso según una de las reivindicaciones anteriores, caracterizado porque los pacientes también presentan al menos uno de los factores de riesgo siguientes: edad, hipertensión, - diabetes - historia de ictus cerebral o embolismo sistémico, - diámetro atrial izquierdo mayor que o igual a 50 mm medido por ecocardiografía, - fracción de eyección ventricular izquierda menor de 40%, medida por ecografía bidimensional.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4599508P | 2008-04-18 | 2008-04-18 | |
FR0803525A FR2930150B1 (fr) | 2008-06-24 | 2008-06-24 | Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6260065A2 true CO6260065A2 (es) | 2011-03-22 |
Family
ID=40001356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10128693A CO6260065A2 (es) | 2008-04-18 | 2010-10-15 | Uso de dronedarona o una sal aceptable farmaceuticamente de esta para la preparacion de un medicamento para regular el nivel de potasio en la sangre |
Country Status (26)
Country | Link |
---|---|
US (1) | US20110124724A1 (es) |
EP (1) | EP2280702A2 (es) |
JP (1) | JP2011518147A (es) |
KR (1) | KR20100135814A (es) |
CN (1) | CN102065857A (es) |
AR (1) | AR072951A1 (es) |
AU (1) | AU2009252898A1 (es) |
BR (1) | BRPI0911198A2 (es) |
CA (1) | CA2721491A1 (es) |
CL (1) | CL2009000919A1 (es) |
CO (1) | CO6260065A2 (es) |
CR (1) | CR11734A (es) |
DO (1) | DOP2010000300A (es) |
EA (1) | EA201071209A1 (es) |
EC (1) | ECSP10010553A (es) |
FR (1) | FR2930150B1 (es) |
IL (1) | IL208751A0 (es) |
MA (1) | MA32356B1 (es) |
MX (1) | MX2010011400A (es) |
NI (1) | NI201000173A (es) |
PE (1) | PE20091777A1 (es) |
SV (1) | SV2010003701A (es) |
TW (1) | TW200946108A (es) |
UY (1) | UY31768A (es) |
WO (1) | WO2009144551A2 (es) |
ZA (1) | ZA201007391B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3195862A1 (en) | 2008-04-17 | 2017-07-26 | Sanofi | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation |
FR2930149B1 (fr) * | 2008-04-17 | 2011-02-18 | Sanofi Aventis | Association de dronedarone avec au moins un diuretique, son application en therapeutique |
FR2930150B1 (fr) * | 2008-06-24 | 2011-01-14 | Sanofi Aventis | Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang |
EP2116239A1 (en) * | 2008-04-29 | 2009-11-11 | Sanofi-Aventis | Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment |
US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
WO2013024411A1 (en) | 2011-08-12 | 2013-02-21 | Lupin Limited | Co-milled formulation of dronedarone |
IN2014KN02584A (es) * | 2012-05-22 | 2015-05-08 | Sanofi Sa | |
TWI732489B (zh) * | 2020-03-17 | 2021-07-01 | 國防醫學院 | 應用心電圖快速偵測鉀離子異常之方法及其系統 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4988513A (en) * | 1990-01-09 | 1991-01-29 | Monsanto Company | Method of treating hypokalemia |
JPWO2006016695A1 (ja) * | 2004-08-10 | 2008-05-01 | 小野薬品工業株式会社 | Ep4アゴニストを含有してなる高カリウム血症の予防および/または治療剤 |
US20070248564A1 (en) * | 2006-04-25 | 2007-10-25 | Roxane Laboratories, Inc. | Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia |
FR2930148A1 (fr) * | 2008-04-17 | 2009-10-23 | Sanofi Aventis Sa | Utilisation de la dronedarone pour la preparation d'un medicament destine a la prevention de l'hospitalisation cardiovasculaire ou de la mortalite |
FR2930149B1 (fr) * | 2008-04-17 | 2011-02-18 | Sanofi Aventis | Association de dronedarone avec au moins un diuretique, son application en therapeutique |
FR2930150B1 (fr) * | 2008-06-24 | 2011-01-14 | Sanofi Aventis | Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang |
-
2008
- 2008-06-24 FR FR0803525A patent/FR2930150B1/fr active Active
-
2009
- 2009-04-16 JP JP2011504572A patent/JP2011518147A/ja not_active Withdrawn
- 2009-04-16 KR KR1020107023065A patent/KR20100135814A/ko not_active Application Discontinuation
- 2009-04-16 CL CL2009000919A patent/CL2009000919A1/es unknown
- 2009-04-16 PE PE2009000533A patent/PE20091777A1/es not_active Application Discontinuation
- 2009-04-16 CA CA2721491A patent/CA2721491A1/en not_active Abandoned
- 2009-04-16 TW TW098112720A patent/TW200946108A/zh unknown
- 2009-04-16 CN CN2009801232874A patent/CN102065857A/zh active Pending
- 2009-04-16 AR ARP090101336A patent/AR072951A1/es unknown
- 2009-04-16 EP EP09754179A patent/EP2280702A2/en not_active Withdrawn
- 2009-04-16 UY UY0001031768A patent/UY31768A/es not_active Application Discontinuation
- 2009-04-16 WO PCT/IB2009/005605 patent/WO2009144551A2/en active Application Filing
- 2009-04-16 EA EA201071209A patent/EA201071209A1/ru unknown
- 2009-04-16 AU AU2009252898A patent/AU2009252898A1/en not_active Abandoned
- 2009-04-16 BR BRPI0911198A patent/BRPI0911198A2/pt not_active IP Right Cessation
- 2009-04-16 MX MX2010011400A patent/MX2010011400A/es not_active Application Discontinuation
-
2010
- 2010-10-08 DO DO2010000300A patent/DOP2010000300A/es unknown
- 2010-10-13 US US12/903,377 patent/US20110124724A1/en not_active Abandoned
- 2010-10-14 CR CR11734A patent/CR11734A/es not_active Application Discontinuation
- 2010-10-14 NI NI201000173A patent/NI201000173A/es unknown
- 2010-10-14 IL IL208751A patent/IL208751A0/en unknown
- 2010-10-14 SV SV2010003701A patent/SV2010003701A/es unknown
- 2010-10-15 CO CO10128693A patent/CO6260065A2/es not_active Application Discontinuation
- 2010-10-15 ZA ZA2010/07391A patent/ZA201007391B/en unknown
- 2010-10-18 EC EC2010010553A patent/ECSP10010553A/es unknown
- 2010-11-03 MA MA33319A patent/MA32356B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
CA2721491A1 (en) | 2009-12-03 |
FR2930150B1 (fr) | 2011-01-14 |
EA201071209A1 (ru) | 2011-04-29 |
AR072951A1 (es) | 2010-10-06 |
MX2010011400A (es) | 2010-11-12 |
BRPI0911198A2 (pt) | 2015-10-13 |
AU2009252898A1 (en) | 2009-12-03 |
JP2011518147A (ja) | 2011-06-23 |
US20110124724A1 (en) | 2011-05-26 |
KR20100135814A (ko) | 2010-12-27 |
EP2280702A2 (en) | 2011-02-09 |
PE20091777A1 (es) | 2009-12-04 |
IL208751A0 (en) | 2010-12-30 |
NI201000173A (es) | 2011-07-20 |
CR11734A (es) | 2010-12-09 |
CN102065857A (zh) | 2011-05-18 |
FR2930150A1 (fr) | 2009-10-23 |
TW200946108A (en) | 2009-11-16 |
DOP2010000300A (es) | 2010-11-15 |
WO2009144551A3 (en) | 2010-01-14 |
UY31768A (es) | 2009-12-14 |
MA32356B1 (fr) | 2011-06-01 |
ZA201007391B (en) | 2012-01-25 |
CL2009000919A1 (es) | 2010-04-09 |
WO2009144551A2 (en) | 2009-12-03 |
SV2010003701A (es) | 2011-01-31 |
ECSP10010553A (es) | 2010-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6260065A2 (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
ES2557303T3 (es) | Agente terapéutico para la estenosis del canal espinal | |
ES2601127T3 (es) | Derivado de pirazol y su uso con fines médicos | |
CL2017002939A1 (es) | Composiciones farmacéuticas tópicas | |
DOP2021000036A (es) | Combinaciones para tratamiendo de ehna/ehgna y enfermedades relacionadas | |
AR079552A1 (es) | Metodo para el tratamiento de la fibrilacion atrial. formulacion farmaceutica | |
CL2019003091A1 (es) | Terapia de combinación. | |
AR104068A1 (es) | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer | |
AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
NI201000181A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona. | |
CO6300842A2 (es) | Asociacion de dronedarona o una de sus sales farmacéuticamente aceptables con al menos un diurético | |
AR072070A1 (es) | Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la cardioversion | |
AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
CY1119308T1 (el) | Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου | |
CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
BR112016012141A2 (pt) | "combinações farmacêuticas, uso das mesmas, e embalagem comercial" | |
MX2018013474A (es) | Acidos carboxilicos para aplicacion en la primera infancia. | |
AR101227A1 (es) | Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor | |
CR11745A (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatina debido a la administracion de dronedarona | |
Shugushev et al. | Results bivalirudin use in actual practice in patients with acute coronary syndrome during percutaneous coronary intervention | |
PE20180314A1 (es) | Composicion topica para el tratamiento del acne juvenil | |
RODRIGUEZ | Synergistic Effect of Lupenone and Caryophyllene Oxide against Trypanosoma cruzi | |
UY31669A1 (es) | "formulación farmacéutica que comprende oxabispidinas /236" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |